Accord Plasma Completes Acquisition of Prothya Biosolutions to Enhance Global Plasma Therapy Capacity

Accord Plasma B.V. Expands Global Reach with Prothya Acquisition

In a significant move within the pharmaceutical sector, Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has finalized its acquisition of Prothya Biosolutions Belgium BV. This successful transaction marks a pivotal expansion of Accord’s capabilities in plasma-derived therapies. The announcement underscores Accord’s commitment to enhancing access to life-saving plasma-derived medications worldwide, particularly in light of the growing global demand for plasma therapies.

Unveiling the Future of Plasma Therapies

Prothya Biosolutions is recognized as one of Europe’s leading plasma fractionators, with state-of-the-art facilities located in Amsterdam and Brussels. The company operates numerous plasma collection centers across Hungary and employs approximately 1,200 highly qualified professionals. This acquisition will not only bolster Accord’s operational capacity but also leverage Prothya’s expertise in the European plasma market, thereby ensuring a steady supply of crucial plasma-derived medicines to meet patient needs across various regions.

Paul Tredwell, the Global CEO of Accord Healthcare, expressed optimism about the merger, stating, “Our objective is to ensure that patients reliant on plasma therapies have reliable access to high-quality treatments. Together with Prothya, we are better positioned to address the escalating global demand for plasma medicines, providing essential therapies to patients worldwide who often experience inadequate prescriptions.”

Merging Strengths for Greater Impact

By integrating Prothya into Accord Plasma, the company is poised to combine Prothya’s established presence and infrastructure in Europe with the large-scale fractionation capabilities of Intas Pharmaceuticals in India. This strategic alignment is expected to accelerate the development and availability of essential plasma-derived medicines (PDMP) and significantly contribute to patient care outcomes.

Accord operates in over 85 countries, which allows them to deliver essential and affordable medications to various health systems globally, significantly improving the lives of patients while catering to the pressing needs of healthcare providers.

Accord Healthcare: A Leader in Innovative Solutions

Headquartered in the UK, Accord Healthcare stands out as one of the fastest-growing pharmaceutical companies in Europe. The organization boasts one of the most prominent market presences among European generic and biosimilar drug manufacturers. Their global footprint facilitates the swift distribution of critical treatments that healthcare professionals can count on.

Accord’s dedication to agility and innovation reflects their mission to continually refine products and enhance patient access. With this acquisition, the company aims to push the boundaries of what's possible in healthcare, utilizing its strengths to benefit communities in need.

Looking Ahead

The acquisition of Prothya Biosolutions by Accord Plasma B.V. is expected to foster increased collaboration and innovation within the plasma therapy sector. This move not only enhances Accord's operational capability but also sets the stage for new possibilities in patient treatment accessibility worldwide. As global healthcare continues to evolve, such strategic acquisitions will play a key role in keeping pace with rising demands and improving health outcomes for countless individuals.

As Accord Plasma B.V. progresses with this integration, it remains steadfast in its promise to revolutionize patient care and uphold its reputation as a leader in the pharmaceutical industry. The company is thoroughly positioned to make a significant impact in the realm of plasma therapies, opening new avenues for enhancing quality of life through modern medicine.